PET/CT in der Onkologie

Zusammenfassung

Limitationen morphologischer und funktioneller bildgebender Verfahren in der onkologischen Diagnostik sind hinlänglich bekannt. So kann die Differenzierung vitaler Tumoranteile von Gewebsnekrose oder Narbengewebe basierend auf der Morphologie schwierig sein, während die nur begrenzte räumliche Auflösung der Positronenemissionstomographie die genaue anatomische Zuordnung einer pathologischen Läsion erschwert. Die kombinierte PET/CT-Bildgebung kompensiert diese Limitationen durch akkurate Bildfusion morphologischer und funktioneller Daten. Diese Übersichtsarbeit erläutert die Grundlagen der PET/CT und beschreibt Möglichkeiten der klinischen Anwendung dieses neuen Untersuchungsverfahrens in der klinischen Onkologie.

Abstract

The limitations of morphologic and functional imaging are well known in oncology. Morphological imaging procedures have difficulties differentiating viable tumor from tumor necrosis or scar tissue, while functional data provided by positron emission tomography (PET) typically supply only limited anatomical information that may render accurate localization of the lesion difficult. Dual-modality PET/CT imaging generates accurately fused functional and morphological data sets in a single examination session thus overcoming these limitations of separate image acquisition. This review addresses PET/CT image acquisition and discusses the value of this new imaging technique for daily oncological routine.

PET/CT - image fusion - anatomic-metabolic imaging - oncology - tumor staging

Literatur

• 1 Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M J. Cancer statistics, 2003.  CA Cancer J Clin. 2003;  53 5-26
• 2 Beyer T, Townsend D W, Brun T. et al . A combined PET/CT scanner for clinical oncology.  J Nucl Med. 2000;  41 1369-79
• 3 von Schulthess G K. Cost considerations regarding an integrated CT-PET system.  Eur Radiol. 2000;  10 (Suppl 3) 377-380
• 4 Goerres G W, Kamel E, Seifert B. et al . Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system.  J Nucl Med. 2002;  43 1469-1475
• 5 Beyer T, Antoch G, Blodgett T, Freudenberg L F, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology.  Eur J Nucl Med Mol Imaging. 2003;  30 588-96
• 6 Antoch G, Freudenberg L S, Egelhof T. et al . Focal tracer uptake: a potential artifact in contrast-enhanced dual- modality PET/CT scans.  J Nucl Med. 2002;  43 1339-1342
• 7 Antoch G, Jentzen W, Freudenberg L S. et al . Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging.  Invest Radiol. 2003;  38 784-789
• 8 Goerres G W, Hany T F, Kamel E, von Schulthess G K, Buck A. Head and neck imaging with PET and PET/CT: artefacts from dental metallic implants.  Eur J Nucl Med Mol Imaging. 2002;  29 367-370
• 9 Halpern B S, Dahlbom M, Waldherr C. et al . Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images.  J Nucl Med. 2004;  45 290-293
• 10 Antoch G, Kuehl H, Kanja J. et al . Dual-Modality PET/CT Scanning with Negative Oral Contrast Agent to Avoid Artifacts: Introduction and Evaluation.  Radiology. 2004;  230 879-885
• 11 Dizendorf E, Hany T F, Buck A, von Schulthess G K, Burger C. Cause and Magnitude of the Error Induced by Oral CT Contrast Agent in CT-Based Attenuation Correction of PET Emission Studies.  J Nucl Med. 2003;  44 732-738
• 12 Nakamoto Y, Chin B B, Kraitchman D L, Lawler L P, Wahl R L. Effects of Nonionic Intraveneous Contrast Agents at PET/CT Imaging: Phantom and Canine Studies.  Radiology. 2003;  227 817-824
• 13 Antoch G, Freudenberg L S, Beyer T, Bockisch A, Debatin J F. To Enhance or Not to Enhance? (18)F-FDG and CT Contrast Agents in Dual-Modality (18)F-FDG PET/CT.  J Nucl Med. 2004;  45 56-65
• 14 Bar-Shalom R, Yefremov N, Guralnik L. et al . Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.  J Nucl Med. 2003;  44 1200-1209
• 15 Lardinois D, Weder W, Hany T F. et al . Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.  N Engl J Med. 2003;  348 2500-2507
• 16 Antoch G, Stattaus J, Nemat A T. et al . Non-Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging.  Radiology. 2003;  229 526-533
• 17 Antoch G, Vogt F M, Freudenberg L S. et al . Whole-Body Dual-Modality PET/CT and Whole-Body MRI for Tumor Staging in Oncology.  Jama. 2003;  290 3199-3206
• 18 Deslauriers J, Gregoire J. Clinical and surgical staging of non-small cell lung cancer.  Chest. 2000;  117 96-103
• 19 Staples C A, Muller N L, Miller R R, Evans K G, Nelems B. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy.  Radiology. 1988;  167 367-372
• 20 Adams S, Baum R P, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.  Eur J Nucl Med. 1998;  25 1255-1260
• 21 Pieterman R M, van Putten J W, Meuzelaar J J. et al . Preoperative staging of non-small-cell lung cancer with positron-emission tomography.  N Engl J Med. 2000;  343 254-261
• 22 Agid R, Sklair-Levy M, Bloom A I. et al . CT-guided biopsy with cutting-edge needle for the diagnosis of malignant lymphoma: experience of 267 biopsies.  Clin Radiol. 2003;  58 143-147
• 23 Hertz G, Reddy V B, Green L. et al . Fine-needle aspiration biopsy of the liver: a multicenter study of 602 radiologically guided FNA.  Diagn Cytopathol. 2000;  23 326-328
• 24 Tsukada H, Satou T, Iwashima A, Souma T. Diagnostic accuracy of CT-guided automated needle biopsy of lung nodules.  AJR Am J Roentgenol. 2000;  175 239-243
• 25 Anderson G S, Brinkmann F, Soulen M C, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.  Clin Nucl Med. 2003;  28 192-197
• 26 Langenhoff B S, Oyen W J, Jager G J. et al . Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.  J Clin Oncol. 2002;  20 4453-4458
• 27 Antoch G, Kanja J, Bauer S. et al . Comparison of PET, CT, and Dual-Modality PET/CT Imaging for Monitoring of Imatinib (STI571) Therapy in Patients with Gastrointestinal Stromal Tumors.  J Nucl Med. 2004;  45 357-365
• 28 Vanuystel L, Vansteenkiste J F, Stroobants S . et al . The impact of 18-F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.  Radiother Oncol. 2000;  55 317-324